| |
40 mg |
80 mg |
| Parameter |
Reference† |
Test* |
Reference† |
Test* |
| No. of subjects |
30 |
30 |
30 |
30 |
| Cmax, μg/ml |
0.13 (0.06) |
0.12 (0.06) |
0.47 (0.29) |
0.48 (0.33) |
| AUC0-t, h·μg/ml |
1.32 (1.02) |
1.40 (1.14) |
2.35 (2.28) |
2.40 (2.51) |
| AUC0-∞, h·μg/ml |
1.85 (1.33) |
2.04 (1.53) |
2.88 (2.73) |
3.02 (2.98) |
| Tmax, h |
2.71 (1.89) |
3.32 (2.38) |
1.09 (0.55) |
1.31 (0.57) |
| Apparent t1/2, h |
10.81 (8.67) |
14.17 (12.50) |
11.73 (11.82) |
12.41 (14.52) |
|
| AUC0-t = AUC from time 0 (baseline) to the last measurable concentration AUC0-∞ = AUC from baseline extrapolated to infinity *Trademark: Raas® (Laboratorios Liomont, S.A. de C.V., Mexico City, Mexico) †Trademark: Micardis® (Boehringer Ingelheim Promeco, S.A.de C.V.,Mexico City, Mexico) |
| Table 1: Pharmacokinetic parameters of telmisartan after a single-dose administration of telmisartan (40 mg or 80 mg) in healthy Mexican male subjects. Values are expressed as means (SD). |
